Immunotherapy: the Mega Weapon to Cure Cancer

Area of Science:

• Oncology
• Immunology
• Genomics

Background:

• Cancer is a complex genomic disease characterized by hallmarks that confer therapeutic resistance.
• Understanding these hallmarks is crucial for developing effective, personalized cancer treatments like immunotherapy.

Purpose of the Study:

• To review current immunotherapies used to overcome cancer's resistance capabilities.
• To discuss the mechanisms and potential of immune checkpoint blockade, CAR T-cell therapy, and oncolytic viral therapy.

Main Methods:

• Review of scientific literature on cancer immunotherapy.
• Analysis of mechanisms for immune checkpoint blockade (anti-PD-1, anti-CTLA-4).
• Examination of Chimeric Antigen Receptor (CAR) T-cell therapy design and oncolytic viral therapy.

Main Results:

• Immune checkpoint blockade enhances lymphocyte responsiveness to cancer cells by inhibiting immune checkpoints.
• CAR T-cell therapy improves T-cell recognition of cancer antigens for targeted immune responses.
• Oncolytic viruses directly lyse cancer cells and enhance immune system vulnerability.

Conclusions:

• Oncolytic viral therapy shows potential as a complementary approach, bridging immune checkpoint blockade and CAR T-cell therapy.
• Combining these immunotherapies may lead to more effective and specific anti-cancer immune responses.